NCT02823990View on ClinicalTrials.gov

TG4010 and Nivolumab in Patients With Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

December 14, 2016

Primary Completion Date

February 24, 2021

Study Completion Date

February 24, 2021

Conditions
Recurrent Non-Small Cell Lung CarcinomaStage I Non-Small Cell Lung CancerStage II Non-Small Cell Lung CancerStage IIIA Non-Small Cell Lung CancerStage IIIB Non-Small Cell Lung CancerStage IV Non-Small Cell Lung Cancer
Interventions
BIOLOGICAL

TG4010

Given SC

BIOLOGICAL

Nivolumab

Given IV

Trial Locations (4)

91010

City of Hope Comprehensive Cancer Center, Duarte

92103

University of California San Diego, San Diego

94115

UCSF Medical Center-Mount Zion, San Francisco

95817

University of California Davis Comprehensive Cancer Center, Sacramento

Sponsors
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Transgene

INDUSTRY

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Karen Kelly

OTHER

NCT02823990 - TG4010 and Nivolumab in Patients With Lung Cancer | Biotech Hunter | Biotech Hunter